For example, anti-SEMA4D plus anti-CTLA-4 resulted in 90% complete tumor rejection (CR) (p<0.0001) in an HNSCC model representative of a T cell inflamed tumor with high MDSC suppression. This evidence concerns the gene SEMA4D and neoplasm.